A Keimyung University research team has reproduced the taste and fragrance of civet coffee, known as “kopi luwak,” by scientifically identifying the digestion and fermentation conditions where civets live.
Consequently, civet coffee could now be mass-produced in a sanitary environment without having to harm animals.
The new civet coffee is available in three varieties, including one with a savory scent and moderate flavor, one with a distinct and fresh flavor, and one with a lot of fruit aroma. More than 40% less caffeine is present than in ordinary civet coffee.
The research team completed a patent application, trademark application, and vegan certification for the research findings, which will be published in academic journals in and outside South Korea.


China Factory Activity Slips in January as Weak Demand Weighs on Growth Outlook
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
China Home Prices Rise in January as Government Signals Stronger Support for Property Market
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets
The Beauty Beneath the Expressway: A Journey from Self to Service
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years
Every generation thinks they had it the toughest, but for Gen Z, they’re probably right
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 



